Richard Kefford

103.6k total citations · 7 hit papers
354 papers, 20.4k citations indexed

About

Richard Kefford is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Richard Kefford has authored 354 papers receiving a total of 20.4k indexed citations (citations by other indexed papers that have themselves been cited), including 247 papers in Oncology, 219 papers in Molecular Biology and 53 papers in Immunology. Recurrent topics in Richard Kefford's work include Melanoma and MAPK Pathways (158 papers), Cutaneous Melanoma Detection and Management (96 papers) and Cancer Immunotherapy and Biomarkers (63 papers). Richard Kefford is often cited by papers focused on Melanoma and MAPK Pathways (158 papers), Cutaneous Melanoma Detection and Management (96 papers) and Cancer Immunotherapy and Biomarkers (63 papers). Richard Kefford collaborates with scholars based in Australia, United States and France. Richard Kefford's co-authors include Georgina V. Long, Richard A. Scolyer, John F. Thompson, Helen Rizos, Alexander M. Menzies, Matteo S. Carlino, Graham J. Mann, Lauren E. Haydu, Peter Hersey and Antoni Ribas and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Richard Kefford

352 papers receiving 20.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

2011 794 citations Georgina V. Long, Alexander M. Menzies et al. Journal of Clinical Oncology profile →
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

2012 719 citations Gerald S. Falchook, Georgina V. Long et al. profile →
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

2013 715 citations Hubing Shi, Willy Hugo et al. Cancer Discovery profile →
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

2019 638 citations Omid Hamid, Caroline Robert et al. profile →
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

2011 507 citations James S. Wilmott, Georgina V. Long et al. Clinical Cancer Research profile →
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

2012 470 citations Hubing Shi, Gatien Moriceau et al. profile →
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

2014 382 citations Helen Rizos, Alexander M. Menzies et al. Clinical Cancer Research profile →

Peers

Richard Kefford

ONCOL

IMMUN

PRM

Grant A. McArthur Australia

Paolo A. Ascierto Italy

Patricia LoRusso United States

Peter Hersey Australia

Jeffrey A. Sosman United States

Georgina V. Long Australia

Igor Puzanov United States

Martin Gore United Kingdom

Brian Druker United States

Adil Daud United States

Grant A. McArthur Australia

Richard Kefford

15.0k ×1.1

ONCOL

15.2k ×1.3

3.8k ×1.0

IMMUN

3.1k ×1.1

5.4k ×2.1

PRM

Citations per year, relative to Richard Kefford Richard Kefford (= 1×) peers Grant A. McArthur

Countries citing papers authored by Richard Kefford

Since Specialization

Citations

This map shows the geographic impact of Richard Kefford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Kefford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Kefford more than expected).

Fields of papers citing papers by Richard Kefford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Kefford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Kefford. The network helps show where Richard Kefford may publish in the future.

Co-authorship network of co-authors of Richard Kefford

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Kefford. A scholar is included among the top collaborators of Richard Kefford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Kefford. Richard Kefford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Jenny, Alexander M. Menzies, Matteo S. Carlino, et al.. (2020). Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research. 26(15). 4064–4071. 62 indexed citations

Wang, Kevin, Alexander M. Menzies, Inês Pires da Silva, et al.. (2018). bcGST—an interactive bias-correction method to identify over-represented gene-sets in boutique arrays. Bioinformatics. 35(8). 1350–1357. 1 indexed citations

Lim, Su Yin, Jenny Lee, Tuba N. Gide, et al.. (2018). Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy. Clinical Cancer Research. 25(5). 1557–1563. 271 indexed citations

Vilain, Ricardo E., Alexander M. Menzies, James S. Wilmott, et al.. (2017). Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Clinical Cancer Research. 23(17). 5024–5033. 191 indexed citations

Robert, Caroline, Antoni Ribas, Omid Hamid, et al.. (2017). Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 36(17). 1668–1674. 336 indexed citations

Kakavand, Hojabr, Robert V. Rawson, Gulietta M. Pupo, et al.. (2017). PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. Clinical Cancer Research. 23(20). 6054–6061. 63 indexed citations

Fox, Peter, Rosemary L. Balleine, Bo Gao, et al.. (2016). Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study. Clinical Cancer Research. 22(13). 3164–3171. 64 indexed citations

Madore, Jason, Ricardo E. Vilain, Alexander M. Menzies, et al.. (2014). PD ‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐ PD ‐1/ PD ‐ L 1 clinical trials. Pigment Cell & Melanoma Research. 28(3). 245–253. 333 indexed citations

Carlino, Matteo S., Carina Fung, Hamideh Shahheydari, et al.. (2014). Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients. Clinical Cancer Research. 21(1). 98–105. 53 indexed citations

10.

Rizos, Helen, Alexander M. Menzies, Gulietta M. Pupo, et al.. (2014). BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact. Clinical Cancer Research. 20(7). 1965–1977. 382 indexed citations breakdown →

11.

Nathanson, Katherine L., Anne‐Marie Martin, Bradley Wubbenhorst, et al.. (2013). Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research. 19(17). 4868–4878. 132 indexed citations

12.

Shi, Hubing, Willy Hugo, Xiangju Kong, et al.. (2013). Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. Cancer Discovery. 4(1). 80–93. 715 indexed citations breakdown →

13.

Carlino, Matteo S., Kavitha Gowrishankar, Catherine A.B. Saunders, et al.. (2013). Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma. Molecular Cancer Therapeutics. 12(7). 1332–1342. 61 indexed citations

14.

Shi, Hubing, Aayoung Hong, Xiangju Kong, et al.. (2013). A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. Cancer Discovery. 4(1). 69–79. 133 indexed citations

15.

Kim, Kevin B., Richard Kefford, Anna C. Pavlick, et al.. (2012). Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. Journal of Clinical Oncology. 31(4). 482–489. 356 indexed citations

16.

Menzies, Alexander M., Lauren E. Haydu, Lydia Visintin, et al.. (2012). Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF -Mutant Metastatic Melanoma. Clinical Cancer Research. 18(12). 3242–3249. 327 indexed citations

17.

Flaherty, Keith T., Sandra J. Lee, Fengmin Zhao, et al.. (2012). Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma. Journal of Clinical Oncology. 31(3). 373–379. 160 indexed citations

18.

Shi, Hubing, Gatien Moriceau, Xiangju Kong, et al.. (2012). Preexisting MEK1 Exon 3 Mutations in V600E/K BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors. Cancer Discovery. 2(5). 414–424. 75 indexed citations

19.

Wilmott, James S., Georgina V. Long, Julie R. Howle, et al.. (2011). Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma. Clinical Cancer Research. 18(5). 1386–1394. 507 indexed citations breakdown →

20.

Davis, Ian D., Richard Kefford, Michael Millward, et al.. (2009). Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial. Clinical Cancer Research. 15(6). 2123–2129. 120 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact